Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer

Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer Shailendra Verma, A. Lane Ilersich Oncologist 2003; 8: 232-240 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Evaluate the combination of docetaxel and capecitabine compared with docetaxel alone for cost effectiveness. Categorize cost differences according to the costs of drugs, hospitalizations, consultations, and other expenditures. Appreciate how combining efficacy quality of life and cost to effectiveness data can be used to support decisions on health care. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar 18, 2005 Most Recent Review: Mar 18, 2005* Most Recent Update: Mar 18, 2005 Date Credit Expires: Apr. 12, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.